Joshua Paul Harvey

Joshua Paul Harvey

Auto-generated profile, based on publicly available information

Joshua Paul Harvey

Ophthalmology Department, King's College Hospital NHS Foundation Trust, London, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2023 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Open access
DWDavid C. S. Ma Wong
David C. S. Ma Wong
JHJoshua P. Ma Harvey
Joshua P. Ma Harvey
NJNeringa Jurkute
Neringa Jurkute
STSara M. Thomasy
Sara M. Thomasy
Mariya MoosajeeMariya Moosajee
Mariya Moosajee
Michael James GilhooleyMichael James Gilhooley
Michael James Gilhooley

30 September 2021 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Closed access
JHJoshua Paul Harvey
Joshua Paul Harvey
PSPaul Edward Sladen
Paul Edward Sladen
PYPatrick Yu-Wai-Man
Patrick Yu-Wai-Man
MCMichael E. Cheetham
Michael E. Cheetham
Background: Inherited optic neuropathies (IONs) cause progressive irreversible visual loss in children and young adults. There are limited disease-modifying treatments, and most patients progress to become severely visually impaired, fulfilling the legal criteria for blind registration. The seminal discovery of the technique for reprogramming somatic nondividing cells into induced pluripotent stem cells (iPSCs) has opened several exciting opportunities in the field of ION research and treatment. Evidence Acquisition: A systematic review of the literature was conducted with PubMed using the following search terms: autosomal dominant optic atrophy, ADOA, dominant optic atrophy, DOA, Leber hereditary optic neuropathy, LHON, optic atrophy, induced pluripotent stem cell, iPSC, iPSC derived, iPS, stem cell, retinal ganglion cell, and RGC. Clinical trials were identified on the ClinicalTrials.gov website. Results: This review article is focused on disease modeling and the therapeutic strategies being explored with iPSC technologies for the 2 most common IONs, namely, dominant optic atrophy and Leber hereditary optic neuropathy. The rationale and translational advances for cell-based and gene-based therapies are explored, as well as opportunities for neuroprotection and drug screening. Conclusions: iPSCs offer an elegant, patient-focused solution to the investigation of the genetic defects and disease mechanisms underpinning IONs. Furthermore, this group of disorders is uniquely amenable to both the disease modeling capability and the therapeutic potential that iPSCs offer. This fast-moving area will remain at the forefront of both basic and translational ION research in the coming years, with the potential to accelerate the development of effective therapies for patients affected with these blinding diseases.

1 August 2022 in Urology
Verified
Journal Article
Closed access
MKMichelle M. Kim
Michelle M. Kim
JHJoshua Harvey
Joshua Harvey
AGAndrew Gusev
Andrew Gusev
JNJenna M. Norton
Jenna M. Norton
SMSaadia Miran
Saadia Miran
TBTamara Bavendam
Tamara Bavendam

9 May 2022 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
JHJoshua Paul Harvey
Joshua Paul Harvey
PYPatrick Yu-Wai-Man
Patrick Yu-Wai-Man
MCMichael Edward Cheetham
Michael Edward Cheetham
Autosomal dominant optic atrophy (DOA) is an inherited optic neuropathy that results in progressive, bilateral visual acuity loss and field defects. OPA1 is the causative gene in around 60% of cases of DOA. The majority of patients have a pure ocular phenotype, but 20% have extra-ocular features (DOA +). We report on a patient with DOA + manifesting as bilateral optic atrophy, spastic paraparesis, urinary incontinence and white matter changes in the central nervous system associated with a novel heterozygous splice variant NM_015560.2(OPA1):c.2356-1 G > T. Further characterisation, which was performed using fibroblasts obtained from a skin biopsy, demonstrated that this variant altered mRNA splicing of the OPA1 transcript, specifically a 21 base pair deletion at the start of exon 24, NM_015560.2(OPA1):p.Cys786_Lys792del. The majority of variant transcripts were shown to escape nonsense-mediated decay and modelling of the predicted protein structure suggests that the in-frame 7 amino acid deletion may affect OPA1 oligomerisation. Fibroblasts carrying the c.2356-1 G > T variant demonstrated impaired mitochondrial bioenergetics, membrane potential, increased cell death, and disrupted and fragmented mitochondrial networks in comparison to WT cells. This study suggests that the c.2356-1 G > T OPA1 splice site variant leads to a cryptic splice site activation and may manifest in a dominant-negative manner, which could account for the patient’s severe syndromic phenotype.


18 November 2015 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
JHJoshua Paul Harvey
Joshua Paul Harvey
An erect chest radiograph demonstrated a pneumopericardium, pneumomediastinum and surgical emphysema in the root of the neck (figure 1). An abdominal radiograph showed a large amount of retroperitoneal free air in the upper abdomen and surrounding the kidney—suggesting a duodenal perforation (figure 2). These findings were not present on the preprocedure film (figure 3).